Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial

200860 citationsJournal Articlehybrid Open Access

Authors

Ioannis Tzanakis · Chania General Hospital ”St. George”

Antonia N. Papadaki · Chania General Hospital ”St. George”

Mingxin Wei · Guangzhou Medical University

Stella Kagia · Chania General Hospital ”St. George”

Vlassios V. Spadidakis · Chania General Hospital ”St. George”

N. Kallivretakis · Chania General Hospital ”St. George”

Dimitrios G. Oreopoulos

Abstract

Our study shows that MgCO(3) administered for a period of 6 months is an effective and inexpensive agent to control serum phosphate levels in hemodialysis patients. The administration of MgCO(3) in combination with a low dialysate Mg concentration avoids the risk of severe hypermagnesemia.

Topics & Keywords

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Magnesium in Health and Disease

UN Sustainable Development Goals

Clean water and sanitation

Publication Details

Published in: International Urology and Nephrology

Volume 40, Issue 1, pp. 193-201

DOI: 10.1007/s11255-007-9300-0

Field-Weighted Citation Impact: 2.31